Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis
BackgroundRelapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic strategies. In this phase 1 study, we evaluated the efficacy and safety of chidamide, azacitidine, cytarabine, aclarubicin and granulocyte colony-stimulating factor (CACAG) in...
Gardado en:
| Principais autores: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-12-01
|
| Series: | Frontiers in Immunology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1698710/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|